ClinicalTrials.gg
WithdrawnNCT04387240Updated May 2, 2022

Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

A Phase 2 interventional study of Artemisinin / Artesunate and placebo in Covid 19 Positive and Corona Virus Infection, sponsored by Princess Nourah Bint Abdulrahman University. Withdrawn at 1 site in Saudi Arabia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Princess Nourah Bint Abdulrahman University · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
did not get enough fund and IRB request

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections.

In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

Read the detailed description

In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load, investigators are testing two groups the one that will take the drug and then compare them to a placebo group that will not take any drug for the treatment in a blinded fashion made by randomization done by our pharmacy team so investigators eliminate risk of bias. Our expectation is to find a total reduction of the hospital stay to 7 days instead of 14 days currently indicating the effectiveness of the medication in eradicating the virus.

02

Conditions studied

  • Covid 19 Positive
  • Corona Virus Infection

Keywords

  • artemisinin
  • Artesunate
03

In context

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.

Browse Coronavirus Infections studies →

Lead sponsor

Princess Nourah Bint Abdulrahman University is the lead sponsor of 31 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient age more than 18 and less than 60 years
  • Symptomatic , positive swab covid-19 patients
  • Patients who have mild to moderate symptoms
  • Patients who have no risk factors like
  • Patients who is not on other medications rather those on supportive care

Exclusion criteria

Exclusion Criteria:

    • Patients who have sever disease- shortness of breath, sick patients or admitted in ICU

      • Patients who are receiving ventilation supports
      • High risk group like :- age more than 60 years, chronic heart diseases, chronic lungs diseases, diabetes, diseases or on immune suppression medications or pregnant women
      • Patients who are on other medications which used as treatment for covid 19
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    intervention group

    this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days

    Drug: Artemisinin / Artesunate

  • Placebo comparator
    placibo

    this group will receive a placebo of the same shape and picture of the study drug

    Other: placebo

Interventions

  • DrugArtemisinin / Artesunate

    Drug pages: ArtemisininStudies of ArtemisininArtemisinin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ArtesunateStudies of ArtesunateArtesunate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative

  • Otherplacebo

    placebo or sham drug will be given to the second arm

06

What researchers measure

Primary outcomes

  1. length of stay in hospital

    absence of the virus shedding evidenced by negative swabs

    Time frame: within the first 6 days intervention

Secondary outcomes

  1. number of ICU admission

    reduction of morbidity and mortality

    Time frame: 14 days

  2. resolution of symptoms

    finding the time that the symptoms disappear

    Time frame: 6 days - 10 day

07

Study locations

1 site
  • Princess Nourah Bint Abdulrahman Univeristy
    Riyadh, Central 11552, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2022; primary completion for Sep 2022, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 13, 2020
StartEst.
Jan 2022
Primary completionEst.
Sep 2022
CompletionEst.
Dec 2022
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04387240
Lead sponsor
Princess Nourah Bint Abdulrahman University
Responsible party
osama y kentab (Clinical Associate Professor of Emergency Medicine, Princess Nourah Bint Abdulrahman University) — Principal investigator
First posted
May 13, 2020
Start date
Jan 2022 (estimated)
Primary completion
Sep 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
May 2, 2022

Study contacts

Osama Kentab, MD
principal investigator · Princess Nourah Bint Abdulrahman University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artemisinin · Artesunate

Start the discussion